Supplementary Table 6.

Main published meta-analyses on testosterone-replacing therapy and cardiovascular events

Author	Year of publication	Issue	Studies included	Number of studies analyzed	Intervention	Number of patients, total (case; control)	Female patients (yes/no)	Klinefelter patients	Thrombophilic patients	Hypogonadism (yes/no)	Observation time (minimum–maximum), months	Result: Increased risk (yes/no)
Fallara et al.82	2022	Mortality, CV events (arterial)	RCT; retrospective registry based	10	TRT vs placebo	179,631 (89,515; 90,116)	No	NR	NR	Yes	6–74.4	No
Hudson et al.17	2022	Mortality, CV and cerebrobascular events (arterial)	Treated-placebo	17	TRT vs placebo	3431 (1750; 1681)	No	NR	NR	Yes	4–36	No
Cannarella et al.83	2022	Heart failure	RCT	7	TRT vs placebo or no treatment	140 (71; 69)	No	NR	NR	Yes	2–12	No
Ayele et al.15	2021	Venous TE	RCT	13	TRT vs placebo or active-comparator	5050 (2636; 2414)	No	NR	NR	NT	3–36	No
Sansone et al.84	2020	Endothelial function (flow-mediated dilation)	RCT, observational	6	TRT vs placebo	Random effects model (86)	No	NR	NR	Yes	0–12	No
Corona et al.10	2018	Major adverse CV events	RCT, pharmaco-epidemiological studies	93	TRT vs placebo	8479 (4653; 3826)	No	NR	NR	NT	11 (mean)	No
Borst et al.54	2014	CV events (arterial)	RCT	35	TRT vs placebo	3703 (2114; 1589)	No	NR	NR	NT	3–62 (mean: 11.9)	Yes (only oral)
Corona et al.85	2011	CV morbidity and mortality	Cross-sectional studies, longitudinal studies, RCT	70	TRT vs placebo	25,299 (total)	No	NR	NR	Yes	3–36	ND
Calof et al.56	2005	CV events (arterial)	Clinical trials	19	TRT vs placebo	1084 (651; 433)	No	NR	NR	NT	3–36	No

RCT: randomized controlled trials; ND: not determined; NR: not reported; NT: not totally; TE: thromboembolism; TRT: testosterone replacement therapy; CV: cardiovascular